New antibody combo shows promise for Hard-to-Treat cancers
Disease control
Ongoing
This early-stage trial tests a new drug called DM919, alone or with pembrolizumab, in 160 adults with advanced solid tumors that have spread or cannot be removed. The main goal is to find a safe and effective dose and see if it can shrink tumors. Participants receive the drug by …
Phase: PHASE1 • Sponsor: D2M Biotherapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC